PET/CT findings in gastric cancer: Potential advantages and current limitations

Saadet Atay-Rosenthal, Richard L. Wahl, Elliot K Fishman

Research output: Contribution to journalArticle

Abstract

18F-fluorodeoxyglucose ( 18F-FDG) as a substrate for tumors with high glucose metabolism has been the most commonly used 18F-FDG-PET radiopharmaceutical in oncologic imaging. However, the usefulness of 18F-FDG-PET in gastric cancer has not yet been fully established. The intent of this review is to help to better understand the impact of 18F-FDG-PET on the imaging of gastric cancer, to offer a greater understanding of how gastric malignancies may present and be recognized on 18F-FDG-PET and to assess the complementary value of PET/CT in gastric cancer staging.

Original languageEnglish (US)
Pages (from-to)241-250
Number of pages10
JournalImaging in Medicine
Volume4
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Fluorodeoxyglucose F18
Stomach Neoplasms
Radiopharmaceuticals
Neoplasm Staging
Neoplasms
Stomach
Glucose

Keywords

  • F-FDG-PET
  • F-fluorodeoxyglucose
  • gastric cancer staging
  • gastric carcinoma
  • PET/CT
  • TNM staging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

PET/CT findings in gastric cancer : Potential advantages and current limitations. / Atay-Rosenthal, Saadet; Wahl, Richard L.; Fishman, Elliot K.

In: Imaging in Medicine, Vol. 4, No. 2, 04.2012, p. 241-250.

Research output: Contribution to journalArticle

Atay-Rosenthal, Saadet ; Wahl, Richard L. ; Fishman, Elliot K. / PET/CT findings in gastric cancer : Potential advantages and current limitations. In: Imaging in Medicine. 2012 ; Vol. 4, No. 2. pp. 241-250.
@article{bf08258422fa4a68a42f26a3e44b0b6f,
title = "PET/CT findings in gastric cancer: Potential advantages and current limitations",
abstract = "18F-fluorodeoxyglucose ( 18F-FDG) as a substrate for tumors with high glucose metabolism has been the most commonly used 18F-FDG-PET radiopharmaceutical in oncologic imaging. However, the usefulness of 18F-FDG-PET in gastric cancer has not yet been fully established. The intent of this review is to help to better understand the impact of 18F-FDG-PET on the imaging of gastric cancer, to offer a greater understanding of how gastric malignancies may present and be recognized on 18F-FDG-PET and to assess the complementary value of PET/CT in gastric cancer staging.",
keywords = "F-FDG-PET, F-fluorodeoxyglucose, gastric cancer staging, gastric carcinoma, PET/CT, TNM staging",
author = "Saadet Atay-Rosenthal and Wahl, {Richard L.} and Fishman, {Elliot K}",
year = "2012",
month = "4",
doi = "10.2217/iim.12.5",
language = "English (US)",
volume = "4",
pages = "241--250",
journal = "Imaging in Medicine",
issn = "1755-5191",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - PET/CT findings in gastric cancer

T2 - Potential advantages and current limitations

AU - Atay-Rosenthal, Saadet

AU - Wahl, Richard L.

AU - Fishman, Elliot K

PY - 2012/4

Y1 - 2012/4

N2 - 18F-fluorodeoxyglucose ( 18F-FDG) as a substrate for tumors with high glucose metabolism has been the most commonly used 18F-FDG-PET radiopharmaceutical in oncologic imaging. However, the usefulness of 18F-FDG-PET in gastric cancer has not yet been fully established. The intent of this review is to help to better understand the impact of 18F-FDG-PET on the imaging of gastric cancer, to offer a greater understanding of how gastric malignancies may present and be recognized on 18F-FDG-PET and to assess the complementary value of PET/CT in gastric cancer staging.

AB - 18F-fluorodeoxyglucose ( 18F-FDG) as a substrate for tumors with high glucose metabolism has been the most commonly used 18F-FDG-PET radiopharmaceutical in oncologic imaging. However, the usefulness of 18F-FDG-PET in gastric cancer has not yet been fully established. The intent of this review is to help to better understand the impact of 18F-FDG-PET on the imaging of gastric cancer, to offer a greater understanding of how gastric malignancies may present and be recognized on 18F-FDG-PET and to assess the complementary value of PET/CT in gastric cancer staging.

KW - F-FDG-PET

KW - F-fluorodeoxyglucose

KW - gastric cancer staging

KW - gastric carcinoma

KW - PET/CT

KW - TNM staging

UR - http://www.scopus.com/inward/record.url?scp=84860209052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860209052&partnerID=8YFLogxK

U2 - 10.2217/iim.12.5

DO - 10.2217/iim.12.5

M3 - Article

AN - SCOPUS:84860209052

VL - 4

SP - 241

EP - 250

JO - Imaging in Medicine

JF - Imaging in Medicine

SN - 1755-5191

IS - 2

ER -